Table 3 Oncological treatment
From: Survival in pregnancy-associated breast cancer patients compared to non-pregnant controls
Variable | Non-pregnant group (N = 55) | Pregnant group (N = 34) | P-value | Missing values | |||||
|---|---|---|---|---|---|---|---|---|---|
Non-pregnant | Pregnant | ||||||||
No | % | No | % | No | % | No | % | ||
Breast surgery | 0.187 | 0 | 1 | 2.9 | |||||
None | 0 | 0 | 2 | 6.1 | |||||
Lumpectomy | 30 | 54.5 | 13 | 39.4 | |||||
Mastectomy | 20 | 36.4 | 14 | 42.4 | |||||
Bilateral mastectomy | 5 | 9.1 | 3 | 9.1 | |||||
Quadrantectomy | 0 | 0 | 1 | 3 | |||||
Lymph node surgery | 0.487 | 0 | 3 | 8.8 | |||||
None | 1 | 1.8 | 2 | 6.5 | |||||
SLNBa | 36 | 65.5 | 18 | 58.1 | |||||
ALNDa | 18 | 32.7 | 11 | 35.5 | |||||
Chemotherapy setting | 0.070 | 1 | 1.8 | 0 | |||||
None | 9 | 16.7 | 2 | 5.9 | |||||
Neoadjuvant | 35 | 64.8 | 19 | 55.9 | |||||
Adjuvant | 10 | 18.5 | 13 | 38.2 | |||||
Radiotherapy | 0.189 | 0 | 0 | ||||||
None | 11 | 20 | 11 | 32.4 | |||||
Yes | 44 | 80 | 23 | 67.6 | |||||
Endocrine Therapy | 0.692 | 1 | 1.8 | 4 | 11.8 | ||||
None | 15 | 27.8 | 11 | 36.7 | |||||
Tamoxifen | 28 | 51.9 | 14 | 46.7 | |||||
Aromatase inhibitor | 11 | 20.4 | 5 | 16.7 | |||||